201 related articles for article (PubMed ID: 25750072)
1. The effects of antiretroviral treatment initiation on cognition in HIV-infected individuals with advanced disease in Pune, India.
Ghate M; Mehendale S; Meyer R; Umlauf A; Deutsch R; Kamat R; Thakar M; Risbud A; Kulkarni S; Sakamoto M; Alexander T; Franklin D; Letendre S; Heaton RK; Grant I; Marcotte TD
J Neurovirol; 2015 Aug; 21(4):391-8. PubMed ID: 25750072
[TBL] [Abstract][Full Text] [Related]
2. Neuropsychological deficits in human immunodeficiency virus type 1 clade C-seropositive adults from South India.
Gupta JD; Satishchandra P; Gopukumar K; Wilkie F; Waldrop-Valverde D; Ellis R; Ownby R; Subbakrishna DK; Desai A; Kamat A; Ravi V; Rao BS; Satish KS; Kumar M
J Neurovirol; 2007 Jun; 13(3):195-202. PubMed ID: 17613709
[TBL] [Abstract][Full Text] [Related]
3. Screening HIV-associated neurocognitive disorders (HAND) among HIV positive patients attending antiretroviral therapy in South Wollo, Ethiopia.
Tsegaw M; Andargie G; Alem G; Tareke M
J Psychiatr Res; 2017 Feb; 85():37-41. PubMed ID: 27821271
[TBL] [Abstract][Full Text] [Related]
4. Disease progression and antiretroviral therapy in newly seropositive HIV subjects in a tertiary care hospital in North India.
Chadha S; Bhalla P; Jha AK; Gautam H; Saini S; Anuradha S; Dewan R
J Infect Dev Ctries; 2013 Feb; 7(2):110-5. PubMed ID: 23416656
[TBL] [Abstract][Full Text] [Related]
5. Randomized double-blind placebo-controlled trial of peptide T for HIV-associated cognitive impairment.
Heseltine PN; Goodkin K; Atkinson JH; Vitiello B; Rochon J; Heaton RK; Eaton EM; Wilkie FL; Sobel E; Brown SJ; Feaster D; Schneider L; Goldschmidts WL; Stover ES
Arch Neurol; 1998 Jan; 55(1):41-51. PubMed ID: 9443710
[TBL] [Abstract][Full Text] [Related]
6. Effect of HIV Subtype and Antiretroviral Therapy on HIV-Associated Neurocognitive Disorder Stage in Rakai, Uganda.
Sacktor N; Saylor D; Nakigozi G; Nakasujja N; Robertson K; Grabowski MK; Kisakye A; Batte J; Mayanja R; Anok A; Gray RH; Wawer MJ
J Acquir Immune Defic Syndr; 2019 Jun; 81(2):216-223. PubMed ID: 30865184
[TBL] [Abstract][Full Text] [Related]
7. Evidence for extended age dependent maternal immunity in infected children: mother to child transmission of HIV infection and potential interventions including sulfatides of the human fetal adnexa and complementary or alternative medicines.
Bhargav H; Huilgol V; Metri K; Sundell IB; Tripathi S; Ramagouda N; Jadhav M; Raghuram N; Ramarao NH; Koka PS
J Stem Cells; 2012; 7(3):127-53. PubMed ID: 23619381
[TBL] [Abstract][Full Text] [Related]
8. Neurological disease: the effects of HIV and antiretroviral therapy and the implications for early antiretroviral therapy initiation.
Wright EJ
Curr Opin HIV AIDS; 2009 Sep; 4(5):447-52. PubMed ID: 20048710
[TBL] [Abstract][Full Text] [Related]
9. HIV-associated neurocognitive disorders: antiretroviral regimen, central nervous system penetration effectiveness, and cognitive outcomes.
Cross HM; Combrinck MI; Joska JA
S Afr Med J; 2013 Sep; 103(10):758-62. PubMed ID: 24079630
[TBL] [Abstract][Full Text] [Related]
10. Dementia and neurocognitive disorders due to HIV-1 infection.
Ances BM; Ellis RJ
Semin Neurol; 2007 Feb; 27(1):86-92. PubMed ID: 17226745
[TBL] [Abstract][Full Text] [Related]
11. HIV-associated cognitive impairment before and after the advent of combination therapy.
Sacktor N; McDermott MP; Marder K; Schifitto G; Selnes OA; McArthur JC; Stern Y; Albert S; Palumbo D; Kieburtz K; De Marcaida JA; Cohen B; Epstein L
J Neurovirol; 2002 Apr; 8(2):136-42. PubMed ID: 11935465
[TBL] [Abstract][Full Text] [Related]
12. Cerebrospinal fluid interferon alpha levels correlate with neurocognitive impairment in ambulatory HIV-Infected individuals.
Anderson AM; Lennox JL; Mulligan MM; Loring DW; Zetterberg H; Blennow K; Kessing C; Koneru R; Easley K; Tyor WR
J Neurovirol; 2017 Feb; 23(1):106-112. PubMed ID: 27400930
[TBL] [Abstract][Full Text] [Related]
13. Cytokines, Hepatic Fibrosis, and Antiretroviral Therapy Role in Neurocognitive Disorders HIV Related.
Falasca K; Reale M; Ucciferri C; Di Nicola M; Di Martino G; D'Angelo C; Coladonato S; Vecchiet J
AIDS Res Hum Retroviruses; 2017 Mar; 33(3):246-253. PubMed ID: 27615271
[TBL] [Abstract][Full Text] [Related]
14. CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy.
Ellis RJ; Badiee J; Vaida F; Letendre S; Heaton RK; Clifford D; Collier AC; Gelman B; McArthur J; Morgello S; McCutchan JA; Grant I;
AIDS; 2011 Sep; 25(14):1747-51. PubMed ID: 21750419
[TBL] [Abstract][Full Text] [Related]
15. Longitudinal neuropsychological test performance among HIV seropositive individuals in Uganda.
Sacktor N; Nakasujja N; Okonkwo O; Skolasky RL; Robertson K; Musisi S; Katabira E
J Neurovirol; 2013 Feb; 19(1):48-56. PubMed ID: 23315423
[TBL] [Abstract][Full Text] [Related]
16. Neurocognitive effects of treatment interruption in stable HIV-positive patients in an observational cohort.
Robertson KR; Su Z; Margolis DM; Krambrink A; Havlir DV; Evans S; Skiest DJ;
Neurology; 2010 Apr; 74(16):1260-6. PubMed ID: 20237308
[TBL] [Abstract][Full Text] [Related]
17. Risk factors for cognitive impairment in HIV-1-infected persons with different risk behaviors.
De Ronchi D; Faranca I; Berardi D; Scudellari P; Borderi M; Manfredi R; Fratiglioni L
Arch Neurol; 2002 May; 59(5):812-8. PubMed ID: 12020265
[TBL] [Abstract][Full Text] [Related]
18. A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
; Danel C; Moh R; Gabillard D; Badje A; Le Carrou J; Ouassa T; Ouattara E; Anzian A; Ntakpé JB; Minga A; Kouame GM; Bouhoussou F; Emieme A; Kouamé A; Inwoley A; Toni TD; Ahiboh H; Kabran M; Rabe C; Sidibé B; Nzunetu G; Konan R; Gnokoro J; Gouesse P; Messou E; Dohoun L; Kamagate S; Yao A; Amon S; Kouame AB; Koua A; Kouamé E; Ndri Y; Ba-Gomis O; Daligou M; Ackoundzé S; Hawerlander D; Ani A; Dembélé F; Koné F; Guéhi C; Kanga C; Koule S; Séri J; Oyebi M; Mbakop N; Makaila O; Babatunde C; Babatounde N; Bleoué G; Tchoutedjem M; Kouadio AC; Sena G; Yededji SY; Assi R; Bakayoko A; Mahassadi A; Attia A; Oussou A; Mobio M; Bamba D; Koman M; Horo A; Deschamps N; Chenal H; Sassan-Morokro M; Konate S; Aka K; Aoussi E; Journot V; Nchot C; Karcher S; Chaix ML; Rouzioux C; Sow PS; Perronne C; Girard PM; Menan H; Bissagnene E; Kadio A; Ettiegne-Traore V; Moh-Semdé C; Kouame A; Massumbuko JM; Chêne G; Dosso M; Domoua SK; N'Dri-Yoman T; Salamon R; Eholié SP; Anglaret X
N Engl J Med; 2015 Aug; 373(9):808-22. PubMed ID: 26193126
[TBL] [Abstract][Full Text] [Related]
19. Valproic acid adjunctive therapy for HIV-associated cognitive impairment: a first report.
Schifitto G; Peterson DR; Zhong J; Ni H; Cruttenden K; Gaugh M; Gendelman HE; Boska M; Gelbard H
Neurology; 2006 Mar; 66(6):919-21. PubMed ID: 16510768
[TBL] [Abstract][Full Text] [Related]
20. Variable benefit in neuropsychological function in HIV-infected HAART-treated patients.
Cysique LA; Maruff P; Brew BJ
Neurology; 2006 May; 66(9):1447-50. PubMed ID: 16682686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
